/
RSS Feed
ROME—It is not acceptable to deny patients with acute myeloid leukaemia the most effective treatments on grounds of age alone, according to Norbert Vey, Professor of Haematology at the Universitée de la Méditerrannée, in Marseille and Head of the Leukaemia/MDS Programme at the Institut Paoli Calmettes. He talks with ecancer radio about the scope for improving treatment for elderly patients who have AML.
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/110325NorbertVeyPODCASTLoRes.mp3]
